HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.048249v1 49/3/354    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soyka, J. D. Articles by Hany, T. F. Search for Related Content PubMed PubMed Citation Articles by Soyka, J. D. Articles by Hany, T. F.

Staging Pathways in Recurrent Colorectal Carcinoma: Is Contrast-Enhanced ¹⁸F-FDG PET/CT the Diagnostic Tool of Choice?

¹ Department of Nuclear Medicine, University Hospital Zuerich, Zurich, Switzerland; ² Department of Visceral and Transplantation Surgery, University Hospital Zuerich, Zurich, Switzerland; and ³ Department of Biostatistics, University of Zuerich, Zurich, Switzerland

Correspondence: For correspondence or reprints contact: Jan D. Soyka, MD, Department of Nuclear Medicine, University Hospital Zuerich, Raemistrasse 100, 8091 Zurich, Switzerland. E-mail: jan.soyka{at}usz.ch

¹⁸F-FDG PET/CT has gained wide acceptance for evaluation of recurrent colorectal carcinoma. However in clinical practice, contrast-enhanced CT (ceCT) is still the first-line restaging tool. The aim of this study was to investigate the value of contrast-enhanced PET/CT (cePET/CT) as a first-line restaging tool with a special focus on the importance of the use of intravenous contrast. Methods: Fifty-four patients (17 women, 37 men; mean age, 60.3 y), referred for restaging of colorectal carcinoma, were examined with cePET/CT. Retrospective analysis was performed by 2 experienced readers by consensus: first, ceCT alone; second, non-cePET/CT; and third, cePET/CT. The number, localization, and diagnostic certainty of lesions were evaluated. Additionally, the therapeutic impact of the findings was determined. In 29 patients, histology, clinical imaging, and clinical follow-up served as the reference standard. In 25 patients, clinical follow-up and imaging served as the reference standard. Results: Overall, non-cePET/CT delivered correct additional information to the ceCT findings in 27 of 54 patients (50%). This occurred in (a) 20 of 30 patients, where ceCT was found to be inconclusive, and in (b) 7 of 24 patients with conclusive ceCT findings, where non-cePET/CT found additional lesions, leading to a therapy modification in 5 patients. Compared with non-cePET/CT, cePET/CT revealed additional information in 39 of 54 patients (72%), with therapeutic relevance in 23 patients. This large number was primarily due to correct segmental localization of liver metastases, which is crucial for surgical therapy planning. Conclusion: On the basis of its higher accuracy and therapeutic impact compared with ceCT, our data suggest that cePET/CT might be considered as the first-line diagnostic tool for restaging in patients with colorectal cancer.

Key Words: colorectal carcinoma • recurrence • ¹⁸F-FDG • PET/CT • staging • contrast

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				F. U Chowdhury, N. Shah, A. F Scarsbrook, and K. M Bradley [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review Postgrad. Med. J., March 1, 2010; 86(1013): 174 - 182. [Abstract] [Full Text] [PDF]

				Y. Nakamoto, K. Togashi, T. Kaneta, H. Fukuda, K. Nakajima, K. Kitajima, K. Murakami, H. Fujii, M. Satake, U. Tateishi, et al. Clinical Value of Whole-body FDG-PET for Recurrent Gastric Cancer: A Multicenter Study Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 297 - 302. [Abstract] [Full Text] [PDF]